Sponsors (3)
The bill aims to protect patients and clinicians from potentially misleading prescription drug advertising and reduce promotion-driven spending, but does so at the cost of increased compliance risk and costs for manufacturers, reduced public access to manufacturer-provided information, and regulatory uncertainty that could raise prices or slow innovation.
Patients with chronic conditions and their clinicians (hospitals, health systems, healthcare workers) may face fewer consumer-targeted ads for recently marketed prescription drugs, reducing exposure to potentially misleading or incomplete marketing claims and encouraging prescribing based on peer-reviewed clinical evidence.
Payers and taxpayers (including Medicare beneficiaries) could see reduced marketing-driven demand for certain drugs, which may lower spending that results from promotion-influenced utilization.
Drug manufacturers will face higher compliance costs and increased legal risk for consumer advertising, which could be passed on as higher drug prices or lead firms to cut promotional activities.
Some patients may receive less information about new treatment options if manufacturers scale back mainstream advertising, making it harder for certain people to learn about available therapies.
A broad statutory definition of advertising and a 30-day lookback period could create regulatory uncertainty and trigger enforcement disputes or litigation, potentially delaying access to information and complicating compliance for health systems and manufacturers.
Based on analysis of 2 sections of legislative text.
Drugs advertised directly to consumers within 30 days are treated as misbranded under the FD&C Act, effectively barring recent DTC promotion without regulatory risk.
Introduced July 22, 2025 by Jerrold Lewis Nadler · Last progress July 22, 2025
Makes drugs whose manufacturer or license holder ran direct-to-consumer advertising in the prior 30 days subject to misbranding rules under the FD&C Act, removing a statutory exception that previously kept some promoted drugs from being treated as misbranded. It defines "direct-to-consumer advertising" to include television, radio, print, digital platforms, and social media and takes effect 30 days after enactment, applying to all drugs regardless of when approved or licensed. The change adds a new disqualifying condition to the FDA misbranding statute, which would limit manufacturers' ability to use consumer-facing marketing without risking misbranding treatment and potential regulatory action under existing drug safety and labeling rules.